BioSpace

FDA’s Summit rejection puts PD-1xVEGF class on notice to establish overall survival

The FDA rejected Summit Therapeutics’ ivonescimab over the weekend, sending a strong message to rival drugmakers Bristol Myers Squibb, BioNTech, Pfizer, Merck and AbbVie.

By BioSpace

1 min read
FDA’s Summit rejection puts PD-1xVEGF class on notice to establish overall survival
AI-generated illustration

Got news to share with the events industry?

Submit a press release or story tip and reach thousands of event professionals.

Get in touch→

More in Health Tech

Related Insights